| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | BIBR-1532 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.8 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |